Exploration of Circular RNA in B-cell Hematologic Malignancies
ConditionLymphoma, B-Cell Refractory
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorRuijin Hospital
About this trial
This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with R/R B-cell malignancies.
Eligibility criteria
Qualifiers
Age ≥ 18 years, any gender.
Able to provide written informed consent.
Diffuse large B-cell lymphoma (DLBCL)
Follicular lymphoma (FL)
Disqualifiers
Prior anticancer therapy-related toxicities unresolved to baseline or ≤ Grade 1 (alopecia and peripheral neuropathy excepted).
Central nervous system (CNS) involvement by lymphoma.
Need for urgent treatment due to tumor mass effect or spinal cord compression.
Known hypersensitivity to any component of IP, including mRNA/LNP-based products.
Trial design
Treatments tested in this trial
- Investigational product (IP)
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Ruijin Hospital
Lead sponsor
RiboX Therapeutics Ltd.
Collaborator
Source ClinicalTrials.gov